PubMed Health⌕ Search

Biomedical subjects

G B Hodge

Publications and source records attributed to G B Hodge.

8 recordsLinked to original sources
PubMed2001

Down-regulation of prostasin serine protease: a potential invasion suppressor in prostate cancer.

BACKGROUND: Prostasin is a serine protease predominantly expressed in normal prostate epithelial cells. The biological function of prostasin has not been determined. METHODS: Western blot and RT-PCR analyses were used to examine the expression of prostasin in prostate cancer cell lines. Immunohistochemistry was used to evaluate prostasin protein expression in human prostate cancer. An in vitro Matrigel invasion assay was used to test the invasiveness of prostate cancer cell lines forced to express recombinant prostasin. RESULTS: Both prostasin protein and mRNA were found to be expressed in normal human prostate epithelial cells and a non-invasive human prostate cancer cell line, the LNCaP, but neither was found in invasive human prostate cancer cell lines DU-145 and PC-3. Prostasin mRNA expression was absent in invasive prostate cancer cell lines of a transgenic mouse model. Immunohistochemistry analysis showed that prostasin protein expression is down-regulated in high-grade prostate cancer. Transfection of DU-145 and PC-3 cells with a full-length human prostasin cDNA restored prostasin expression and reduced the in vitro invasiveness by 68 and 42%, respectively. CONCLUSIONS: Our data indicate that prostasin may be implicated in normal prostate biology and is able to suppress prostate cancer invasion in vitro.

Blotting, Western↗
PubMed1999

Does long-term finasteride therapy affect the histologic features of benign prostatic tissue and prostate cancer on needle biopsy? PLESS Study Group. Proscar Long-Term Efficacy and Safety Study.

OBJECTIVES: Finasteride, a common agent used to treat benign prostatic hyperplasia (BPH), inhibits 5-alpha-reductase. Testosterone is converted by 5-alpha-reductase to the more potent dihydrotestosterone, which is the primary androgen in the prostate. Leuprolide is a stronger antiandrogen that is used to downstage prostate cancer before radical prostatectomy. Leuprolide induces marked atrophy of prostate carcinoma cells, which sometimes makes pathologic diagnosis of cancer difficult, although evaluation at radical prostatectomy is easier than at biopsy. It is unknown whether finasteride produces similar changes, which would result in greater diagnostic difficulty because such changes would be seen on biopsy to rule out cancer in men with suspicious clinical findings treated for BPH. The current study investigated the histologic effects of finasteride therapy on human prostate cancer and benign prostatic tissue on needle biopsy. METHODS: In blinded manner, we reviewed 53 needle biopsy specimens showing prostate carcinoma (35 treated with finasteride, 18 with placebo). Also reviewed in blinded manner were 50 benign needle biopsy specimens (25 treated with finasteride, 25 with placebo). The Gleason score, number of cores involved, percentage cancer involvement in a core, percentage of atrophic changes in cancer cells, presence of mitoses, blue-tinged mucinous secretions, prominent nucleoli, and high-grade prostatic intraepithelial neoplasia were documented for each case in the cancer group. The percentage of atrophy, basal cell hyperplasia, transitional metaplasia, chronic inflammation, and stromal proliferation was documented for each case in the benign group. RESULTS: No significant histologic differences were present in either the benign or cancer group between cases treated with finasteride and placebo. CONCLUSIONS: We conclude that finasteride treatment for BPH does not cause difficulty in the diagnosis of cancer in prostate needle specimens. It is possible that there are severely atrophic areas resulting from finasteride treatment that are undersampled. However, the conclusion that cancer seen on needle biopsy in men treated with finasteride is unaltered and readily identified as cancer remains valid.

Aged↗
PubMed1985

Urachal carcinoma.

The clinical and morphologic features in 14 cases of urachal adenocarcinoma are reviewed. The disease occurred more frequently in men than in women. Seven patients (50%) remain alive and currently free of disease at periods ranging from fifteen months to ten years (median: 6 years). Neither the histologic appearance nor the differentiation of the tumor appeared to affect prognosis. It is concluded that the criteria previously recommended to establish the diagnosis of this rare malignancy were too restrictive.

Adenocarcinoma↗
PubMed1985

Oat cell carcinoma of lung masquerading as prostatic carcinoma.

We believe this is the second case of oat cell carcinoma metastatic to the prostate to be reported. The patient was treated for prostatic carcinoma diagnosed by rectal examination. Subsequent biopsy confirmed oat cell carcinoma and led to the discovery of pulmonary carcinoma. Tumors metastatic to the prostate are rare and are identified when they result in urologic symptoms. A review of tumors metastatic to the prostate is presented.

Aged↗
PubMed1985

Benign retroperitoneal neurilemoma without von Recklinghausen's disease: a rare occurrence.

We describe a rare case of a primary retroperitoneal neurilemoma that was confused initially on ultrasonography and computerized tomography for a renal carcinoma. These tumors vary in vascularity on arteriography, are more often solid than cystic and usually are benign in the absence of von Recklinghausen's disease. The preferred treatment is wide surgical excision.

Carcinoma, Renal Cell↗
PubMed1984

Radiation therapy versus delayed androgen deprivation for stage C carcinoma of the prostate.

Seventy-three patients with prostatic adenocarcinoma who were believed to have disease limited to the pelvis without evidence of node or bone extension were assigned randomly to either full-field pelvic radiation (40) or delayed hormonal therapy (33). The interval to first evidence of treatment failure was used as the end point of the study. Failures occurred in 13 patients who received radiation therapy and 11 who received delayed hormonal therapy. No difference in disease response could be identified between the 2 treatment groups.

Adenocarcinoma↗
PubMed1983

Penile prosthesis in Peyronie's disease.

Many patients with Peyronie's disease suffer severe penile curvature, impotence, and respond poorly to conservative management. Sixteen patients with intractable Peyronie's disease had surgical incision of Peyronie's plaque and insertion of semi-rigid or inflatable penile implants. Patients had satisfactory results with elimination of curvature and resumption of coitus. Surgical procedures are indicated for impotent patients with Peyronie's disease who are unresponsive to conservative treatment.

Adult↗